Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBP

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

- PMLiVE

Quality in Care’s 2015 diabetes programme launches at Diabetes UK

Now open for entries to celebrate best practice in NHS diabetes care

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

UK flag

NHS staff blame cost-cutting for poor diabetes outcomes

Lack of local and national leadership also cited in new ABPI report

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

AbbVie to acquire cancer biopharma Pharmacyclics for $21bn

Comes six months after the US firm pulled out of a $54bn deal with Shire

National Institute for Health and Care Excellence NICE logo

Patients should have a say in their medication, claims NICE

Also states health practitioners should be able to share information

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

- PMLiVE

Greater Manchester to control its share of the NHS budget

The north-west English region accounts for 5% of the country's health spending

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links